ALNY
Alnylam Pharmaceuticals, Inc.
stock NASDAQ

If you prefer momentum, ADMA is up about 12.97% over 12 weeks and continues to print higher lows. RIGL is stronger over that same window at roughly 22.40%. ALNY is the large cap barometer with a 71.9% yearly move heading into 2026, a reminder that oncology and RNA stories still get paid when data cooperates.
For asymmetry, MYNZ is up about 2% today and sits in a different bucket. It is a low float diagnostics name with Europe distribution for ColoAlert and a visible catalyst stack. AACR in April should bring pancreatic verification details. CRC feasibility is guided to wrap in the first half of 2026, a key step toward the U.S. pivotal with Quest as the scale partner if approval follows. Into that setup, I want two things before sizing up. Volume above the 10 day average and a VWAP reclaim that holds on a retest.
Which mix fits your plan today. Stick with trend names like ADMA and RIGL, or pair one of those with an underdog swing like MYNZ for optionality?

If you prefer momentum, ADMA is up about 12.97% over 12 weeks and continues to print higher lows. RIGL is stronger over that same window at roughly 22.40%. ALNY is the large cap barometer with a 71.9% yearly move heading into 2026, a reminder that oncology and RNA stories still get paid when data cooperates.
For asymmetry, MYNZ is up about 2% today and sits in a different bucket. It is a low float diagnostics name with Europe distribution for ColoAlert and a visible catalyst stack. AACR in April should bring pancreatic verification details. CRC feasibility is guided to wrap in the first half of 2026, a key step toward the U.S. pivotal with Quest as the scale partner if approval follows. Into that setup, I want two things before sizing up. Volume above the 10 day average and a VWAP reclaim that holds on a retest.
Which mix fits your plan today. Stick with trend names like ADMA and RIGL, or pair one of those with an underdog swing like MYNZ for optionality?